Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference study of subcutaneous versus intravenous trastuzumab in HER2-positive advanced breast cancer
2012-004928-38Phase 3Completed
- Sponsor
- GEICAM
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by GEICAM. Started Dec 2012; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-004928-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004928-38.